**CURRICULUM VITAE OF DR. GERALD MAARMAN**

# PERSONAL INFORMATION

* Office number: 0219389392
* Email address: gmaarman@sun.ac.za

# EMPLOYMENT

* 2022-present: Senior Lecturer, Division of Medical Physiology (NRF Y-2 Rated, H-index 14).
* 2018–2022: Lecturer, Division of Medical Physiology.
* 2017-2019: Research Manager – Desmond Tutu TB Centre, Stellenbosch University (SU)
* 2014-2016: Postdoctoral research fellow –University of Cape Town (UCT).
* 2011-2012: Visiting researcher – Medizinische Hochschule Hannover (Germany).

# EDUCATION

* 2024: PGDip Theology (SU)
* 2014: Ph.D. Medical Physiology in Medicine (SU).
* 2020: MSc. Medical Physiology (SU).
* 2007: BSc. Honours Medical Physiology (SU).
* 2007: BSc. Human Life Sciences (SU).
* 2002: Grade 12 (Matric, Eersterivier Secondary School).

**CONTINUOUS PROFESSIONAL DEVELOPMENT**

* Certificate, Good Clinical Practice (GCP)
* Certificate, NIH Human Subjects Protection
* Certificate, Golden Key Society
* Certificate, Accreditation of Car, Use and Handling of Laboratory Animals
* Certificate, Basic Communication in Xhosa
* Certificate, Scientific Writing Skills
* Certificate, Engineer Drawings (N1, N2)
* Certificate, Terminal & Home-Based Care
* Certificate, Trauma Counselling
* Certificate, HIV/AIDS peer-counselling
* Certificate, Basic & Intermediary First Aid

**Field of Study, Major Research Topics and Scientific Interests**

* My research niche is mitochondrial bioenergetics & metabolism in diseases like pulmonary arterial hypertension (PAH), cancer, Parkinson’s disease & a range of cardiovascular diseases. Many of these diseases either have no cure or impactful treatment or the pathophysiology is not well understood. Given the key role of mitochondria in health and disease, my research focuses on delineating mitochondrial processes and mechanisms linked to the development of disease and their role in novel/experimental therapeutic applications. I have published several studies that aimed to better understand the involvement of mitochondrial bioenergetics & metabolism in diseases like cardiovascular disease. I have also established a metabolic lab at Stellenbosch University, which houses the University’s first High-Resolution Respirometer, which uses the latest technology to measure mitochondrial bioenergetics & metabolism pathways. I currently have 788 citations and an H-index of 14, based on scholar.

# RESEARCH SKILLS

# Oroboros (High-Resolution FluoRespirometer).

# Seahorse XF analyzer

# HansaTech Oxygraph

# Isolated rat heart perfusion system (working heart and Langendorff perfusions)

# *In vivo* pulmonary arterial banding surgery in mice and rats

# *In vivo* right heart catheterisation in mice and rats

# Echocardiography of rats and mice

# ELISA assay kits

# Cell culture (H9C2, C2C12, L6, HepG2, U-118MG, U-87, HUVEC, MCF7, MDA-MB-231)

# Clinical studies (observational and RCT)

# Clinical Research/Project Management

# Basic histology.

# Basic RNA isolation and RT-PCR

# Western blots

# Basic flow cytometry

# INVOLVEMENT IN UNDERGRADUATE TEACHING

* Molecular biology (Life Forms 111)
	+ MBChB, BSc Physiotherapy, BSc Dietetics – phase 1, Class size: ~ 400
* Cardiovascular Physiology (Fundamentals of Physiology 178)
	+ B. Occ. Ther. first year, Class size: 73
* Cardiovascular Physiology (271)
	+ MBChB second year, Class size: ~ 300
* Cardiovascular Physiology (Form and Function)
	+ MBChB first year, Class size: ~ 500
* Gastro-intestinal tract Physiology (Allied Health Sciences)
	+ 2nd year BSc Physiotherapy, BSc Dietetics and Bachelor of Nursing and Midwifery students, Class size: 136
* Gastro-intestinal tract Physiology (Form and Function)
	+ MBChB first year, Class size: ~ 500
* Gastro-intestinal tract Physiology (Human Physiology 171)
	+ Allied Health students first year, Class size: 100
* Gastro-intestinal tract Physiology (Fundamentals of Physiology 178)
	+ B. Occ. Ther. first year, Class size: 73
* Musckuloskeletal Physiology (371)
	+ MBChB third year, Class size: 328
* Musckuloskeletal Physiology (Human Physiology 171)
	+ Allied Health students first year, Class size: 100
* Immunology (Cellular Physiology F344)
	+ F344 third year, Phase I Class size: 186
* Immunology (Human Physiology 171)
	+ Allied Health students first year, Class size: 100
* Immunology (Essentials of Human Physiology 271)
	+ Second year (nursing students), Class size: 50
* Respiratory Physiology (271)
	+ MBChB second year, Phase I Class size: 300
* Supervisor for MBChB elective IV
	+ Three thus far.

# INVOLVEMENT IN POSTGRADUATE TEACHING

* Coordinator of BSc. Honours program in Medical Physiology (2018 – currently).
* Cardiopulmonary diseases and research, and academic writing to the Honours BSc. Medical Physiology students, a class size of 12-17 students (annually).
* Implement administrative duties (marking, reviewing of assessments, reports).
* Provide virtual teaching and assessment to MMed students.

# CURRICULUM DEVELOPMENT

* A Renewed Curriculum Project Committee (RCPC) member, at the Faculty of Medicine & Health Sciences. I play a part in developing and implementing a new curriculum for medical school (Form & Function, Health & Wellness).
* Module co-lead for the new Cardiovascular System and Gastro-intestinal System (Form and Function).
* Module cycle lead for the new Health and Wellness module.

**Postdoctoral research fellow:** Dr. Olakunle Sanni(2022-2025).

**Technical assistants/Research support staff:**

* Mr Sadam Parker
* Miss Danelle Botha
* Mr. Jaden Fillies

**Postgraduate student supervision (Main supervisor) – COMPLETED.**

* PhD, Thato Kgatla (Cum Laude)
* MSc, Carmen Payne (Summa Cum Laude)
* MSc, Dr Steve Jacobs (Cum Laude)
* MSc, Sara Shaboodien (Cum Laude)
* BSc. Hons, Cornel Vlok (Cum Laude)
* BSc. Hons, Dinisha Giga (Cum Laude)
* BSc. Hons, Steve Jacobs
* BSc. Hons, Lindiwe Malefane (Cum Laude)
* BSc. Hons, Sara Shaboodien (Cum Laude)

**Postgraduate student supervision (Main supervisor) – enrolled.**

* PhD, Joshua Matthee (1st year)
* MSc, Amy Pretorius (2nd year)
* MSc, Chrisstoffel Jumaar (2nd year)
* MSc, Garth Wentley (2nd year)
* MSc, Lindiwe Malefane (1st year)

**Postgraduate student supervision (CO-supervisor) – COMPLETED.**

* PhD, Melisse Sharne Erasmus (MRC BRIP)
* PhD, Siddiqah George (UCT)
* MSc, Sharnay Naidoo (MRC BRIP) (Cum Laude)
* MSc, Pamela Sithelo (SU)
* MSc, Caitlin Odendaal (SU) (Cum Laude)
* BSc. Hons, Erin Robson (SU) (Cum Laude)
* BSc. Hons, Jeffrey Pieterse (SU) (Cum Laude)
* BSc. Hons, Brittany Andrew (UCT)
* BSc. Hons, Priska Osiki (UCT)

**Postgraduate student supervision (CO-supervisor) – ENROLLED.**

* PhD, Vuyolwethu Mbombela (SU)
* PhD, Amy Buck (SU)
* MSc, Kabelo Mfisa (SU)
* MSc, Tamera Moodley (SU)
* MSc, Natasha Marnewick (SU)

# EXTERNAL DUTIES

* External examiner - 4x PhD dissertations
* External examiner 5x MSc dissertations
* Served as invited peer-reviewer to close to 12 journals (national & international)
* External moderator - Exit level module FLGX 329 (2nd semester 2021), Cardiovascular Physiology applications, of the North-West University for 2021.
* External moderator – University of Limpopo, SPLA031 course (Environmental influences on the human body).
* Co-Editor – *Frontiers in Endocrinology* 2021 (impact factor 5.555)

# Institutional involvement and social responsiveness

* Member of the MBChB selection panel (B1, B2, B3 annual selections).
* Member of the FMHS Dean’s Advisory Committee for Transformation (DACT).
* Member of the Equality Champions (FMHS).
* Member of the Division of Medical Physiology’s Social Impact Committee (SICEMAC).
* Youth & community development agent (SAICA, Scimathus, SU, Local churches, and NPOs).
* SASCAR exco member with a social impact portfolio.
* Recent member of At Heart (Stellenbosch NPO) and SCAN.

# SUCCESSFUL RESEARCH GRANTS (MAIN PRINCIPAL INVESTIGATOR)

* MRC-SIR = R600 000 (2023-2025)
* NRF support grant for Y-rated researchers = R300 000 (2023-2024)
* NRF Incentive funding SU = R60 000 (2020-2022)
* SARC grant = R 1.52 million (2023-2025)
* PVRI – Imperial College London = R1 093872,23 (2024-2025)
* Postdoc Funding SU Subcommittee C = R220 000 (2022-2023)
* FMHS TRA grant – R60 000 (2022-2023)
* ACU Early Career Conference Grant = R36 000 (2022)
* SU funding support for equipment = R511 000 (2023)
* SA-MRC SIR: R600 000 (2017-2019)
* SARC grant: R842 406 (2017-2019)
* Early Career Research Award FMHS = R 112 463 (2018)
* NRF Equipment Related Travel: R135 000 (2022)
* Harry Crossley Project Funding: R31 500 (2022)
* Divisional research grant: R50 000 (2019)
* FMHS equipment grant: R784 000 (2019)

## **OFFICIAL RESEARCH COLLABORATIONS**

* Prof. Ghazwan Butrous (Imperial College of London, UK).
* Prof. Yong-Xiao Wang (Albany Medical Center, USA).
* Prof. Russel J. Reiter (San Antonio, Texas, USA).
* Prof. Denise Hilfiker-Kleiner (Hannover, Germany).
* Prof. Ralph Schermuly (Giessen, Germany).
* Prof. Rainer Schulz (Essen, Germany).
* Prof. Brian Allwood (Division of Pulmonology, SU).
* Prof. Sandrine Lecour (Cape Heart Institute, UCT).
* Prof. Karen Sliwa-Hahnle (Cape Heart Institute, UCT).
* Prof. Friedrich Thienemann (Cape Heart Institute, UCT).
* Prof. Novel Chegou (SUN -IRG, SU)
* Prof. Hans Strijdom (CARMA, SU).
* Prof. Rabia Johnson (MRC SA, BRIP)
* Prof. Faadiel Essop (CARMA, SU).

# PUBLISHED PAPERS

[1] Malefane, L. and G. Maarman, Post-tuberculosis lung disease and inflammatory role players: Can we characterise the myriad inflammatory pathways involved to gain a better understanding? Chem Biol Interact, 2024. 387: p. 110817.

[2] Payne, C., et al., A pulmonary arterial hypertension diagnostic algorithm for a third-world context: Symquick. J Investig Med, 2023. 71(5): p. 542-544.

[3] Louw, E., et al., The prevalence of pulmonary hypertension after successful tuberculosis treatment in a community sample of adult patients. Pulm Circ, 2023. 13(1): p. e12184.

[4] Jacobs, S., et al., Gut microbiota crosstalk mechanisms are key in pulmonary hypertension: The involvement of melatonin is instrumental too. Pulm Circ, 2023. 13(3): p. e12277.

[5] Grant-McAuley, W., et al., Population-level analysis of natural control of hiv infection in zambia and south africa: Hptn 071 (popart). J Int AIDS Soc, 2023. 26(10): p. e26179.

[6] Maarman, G.J., Reviewing the suitability of mitochondrial transplantation as therapeutic approach for pulmonary hypertension in the era of personalized medicine. Am J Physiol Lung Cell Mol Physiol, 2022. 322(5): p. L641-L646.

[7] Maarman, G.J., Pulmonary hypertension in developing countries: Limiting factors in time to diagnosis, specialised medications and contextualised recommendations. Afr J Thorac Crit Care Med, 2022. 28(1).

[8] Maarman, G.J. and S. Lecour, Melatonin against pulmonary arterial hypertension: Is it ready for testing in patients? Cardiovasc J Afr, 2021. 32(2): p. 111-112.

[9] Bell-Mandla, N.F., et al., Improving retention of community-recruited participants in hiv prevention research through saturday household visits; findings from the hptn 071 (popart) study in south africa. BMC Med Res Methodol, 2021. 21(1): p. 242.

[10] Maarman, G.J., J. Shaw, and B. Allwood, Pulmonary hypertension in majority countries: Opportunities amidst challenges. Curr Opin Pulm Med, 2020. 26(5): p. 373-383.

[11] Maarman, G.J., G. Chakafana, and K. Sliwa, World heart day: A world heart federation communique on the future of basic sciences and translational medicine in global cardiovascular research. Am J Physiol Lung Cell Mol Physiol, 2020. 319(3): p. L545-L546.

[12] Maarman, G.J., Making a case for metallothioneins conferring cardioprotection in pulmonary hypertension. Med Hypotheses, 2020. 137: p. 109572.

[13] Eshleman, S.H., et al., Determination of hiv status and identification of incident hiv infections in a large, community-randomized trial: Hptn 071 (popart). J Int AIDS Soc, 2020. 23(2): p. e25452.

[14] Sloot, R., et al., Variation in hiv prevalence and the population-level effects of antiretroviral therapy in reducing tuberculosis incidence in south africa. S Afr Med J, 2018. 108(8): p. 12370.

[15] Nduhirabandi, F. and G.J. Maarman, Melatonin in heart failure: A promising therapeutic strategy? Molecules, 2018. 23(7).

[16] Maarman, G.J. and R.J. Reiter, Melatonin therapy for blunt trauma and strenuous exercise: A mechanism involving cytokines, nfkappab, akt, maf(bx) and murf-1. J Sports Sci, 2018. 36(16): p. 1897-1901.

[17] Maarman, G.J., Pulmonary arterial hypertension and the potential roles of metallothioneins: A focused review. Life Sci, 2018. 214: p. 77-83.

[18] Kriel, J., et al., Coordinated autophagy modulation overcomes glioblastoma chemoresistance through disruption of mitochondrial bioenergetics. Sci Rep, 2018. 8(1): p. 10348.

[19] Allwood, B.W., et al., Post-pulmonary tuberculosis complications in south africa and a potential link with pulmonary hypertension: Premise for clinical and scientific investigations. S Afr Med J, 2018. 108(7): p. 12339.

[20] Webster, I., et al., Myocardial susceptibility to ischaemia/reperfusion in obesity: A re-evaluation of the effects of age. BMC Physiol, 2017. 17(1): p. 3.

[21] Maarman, G.J., et al., Novel putative pharmacological therapies to protect the right ventricle in pulmonary hypertension: A review of current literature. Br J Pharmacol, 2017. 174(7): p. 497-511.

[22] Maarman, G.J., et al., Review of a causal role of fructose-containing sugars in myocardial susceptibility to ischemia/reperfusion injury. Nutr Res, 2017. 42: p. 11-19.

[23] Maarman, G.J., et al., Melatonin protects against uric acid-induced mitochondrial dysfunction, oxidative stress, and triglyceride accumulation in c(2)c(12) myotubes. J Appl Physiol (1985), 2017. 122(4): p. 1003-1010.

[24] Maarman, G.J., Editorial commentary: "Discovery of a murine model of clinical pulmonary arterial hypertension: Mission impossible?" By dai and zhao. Trends Cardiovasc Med, 2017. 27(4): p. 237-238.

[25] Maarman, G.J., Natural antioxidants as potential therapy, and a promising role for melatonin against pulmonary hypertension. Adv Exp Med Biol, 2017. 967: p. 161-178.

[26] Ojuka, E., et al., Measurement of beta-oxidation capacity of biological samples by respirometry: A review of principles and substrates. Am J Physiol Endocrinol Metab, 2016. 310(9): p. E715-23.

[27] Madlala, H.P., G.J. Maarman, and E. Ojuka, Uric acid and transforming growth factor in fructose-induced production of reactive oxygen species in skeletal muscle. Nutr Rev, 2016. 74(4): p. 259-66.

[28] Maarman, G., et al., Melatonin as a preventive and curative therapy against pulmonary hypertension. J Pineal Res, 2015. 59(3): p. 343-53.

[29] Kelly-Laubscher, R.F., et al., Cardiac preconditioning with sphingosine-1-phosphate requires activation of signal transducer and activator of transcription-3. Cardiovasc J Afr, 2014. 25(3): p. 118-23.

[30] Maarman, G., et al., A comprehensive review: The evolution of animal models in pulmonary hypertension research; are we there yet? Pulm Circ, 2013. 3(4): p. 739-56.

[31] Maarman, G., et al., Effect of chronic cpt-1 inhibition on myocardial ischemia-reperfusion injury (i/r) in a model of diet-induced obesity. Cardiovasc Drugs Ther, 2012. 26(3): p. 205-16.

**MANUSCRIPTS UNDER PEER REVIEW**

[1] Wentley G, Butrous G, Lecour S, Wang YX and, **MAARMAN G**, the intriguing effects of melatonin on mitochondrial bioenergetics and metabolism of healthy C2C12 myotubes, *Physiological Reports*.

[2] Jacobs S, Payne C, Shaboodien S Kgatla T, A Pretorius, C Jumaar, **Maarman G**, and Sanni, Reviewing pulmonary hypertension and the potential of “drug” repurposing, and the special role for African medicinal plants and herbs, *Amer J Phys Lung Cell Phys.*

[3] Kgatla T, Shaboodien S, Payne C, Parker S, Vlok C Lopes J, Strijdom H, Marais E and **MAARMAN G**, Rooibos induced cardioprotection in an H9C2 model of angiotension-II induced hypertrophy and apoptosis.

[4] Shadoodien S, Parker MS, Payne C, Vlok C, and **Maarman G**, Fermented Aspalathus linearis (Rooibos) extract attenuates isoproterenol-induced H9C2 hypertrophy.

[5] O Sanni, and **MAARMAN G**, Rooibos protects against hypoxia-reoxygenation, via the SAFE pathway.

[6]C Payne, E du Toit, N Baines, Strijdom, D Maree, S Schultz, B Botha, M Feyasa, B Allwood, and **Maarman G**, Pulmonary hypertension in a cohort with previously treated or active tuberculosis is underpinned by disrupted mitochondrial metabolism.

[7] C Payne, O Sanni, E du Toit, N Baines, B Allwood, and **Maarman G**, Respiratory analysis of coupled mitochondria in cryopreserved peripheral blood mononuclear cells isolated from whole blood in patients.

[8] Kgatla TM, Sanni O, and **Maarman G**, Cardioprotection with herbal plants and the role of mitochondrial function and regulation.

[9]C Jumaar, S Jacobs, O Sanni, E Louw, N Baines, D Maree, B Botha, B Allwood, and G Maarman, Evidence from a lung tuberculosis cohort sub-study suggests that endothelial dysfunction or vascular remodelling may be present in a post-tuberculosis context.

[10] L Malefane, S Jacobs (co-first author), C Payne, O Sanni, E Louw, N Baines, D Maree, S Schultz, S Windvogel, H Strijdom, B Botha, B Allwood, G Maarman, Delineating the involvement of inflammatory pathways in post tuberculosis lung disease in a South African cohort: an observational study.

[11] S Jacobs and G Maarman, Reviewing and highlighting novelties and uncertainties in pulmonary TB, and post-TB lung disease. An invited review for a special issue of Pulmonary Circulation.

[12] S Jacobs and G Maarman, A brief review of the risk factors associated with post-tuberculosis lung disease, and gaps in the literature regarding pathophysiology. An invited review for a special issue of Pulmonary Circulation

[13] Thato, RB and mitochondrial paper

[14] Thato, RB and MT agonist and inhibitor paper

[15] Candice paper

[16] Francis paper

[17] Caitlin paper

[18] TB mouse model paper

**INVITED KEYNOTE ADDRESSES**

[1] **MAARMAN G**, Post-TB Pulmonary Hypertension - through the lens of a South African cohort and experimental model, PVRI Annual Congress, London, UK, January 2024, **INVITED KEYNOTE ADDRESS.**

[2] **MAARMAN G**, The role of mitochondrial in cardio-pulmonary vascular research: a research journey, University of Limpopo, Polokwane, 19-23 September 2023. **INVITED KEYNOTE ADDRESS.**

[3] **MAARMAN G**, Shaw J, Allwood, Recent developments in clinical PAH research at Tygerberg Hospital, South Africa: preliminary data, PVRI Annual Congress, Peru, April 2020 **– INVITED KEYNOTE ADDRESS.**

[4] **MAARMAN G**, Sliwa K and Lecour S, Characterisation of mitochondrial function in a model of pulmonary arterial hypertension and right ventricular failure, 5th Annual International Mitochondrial Physiology School, Cape Town, South Africa May 2015, **INVITED KEYNOTE ADDRESS.**

[5] **MAARMAN G**, Recent developments in PAH Basic Science research and Animal models, SA Heart Annual Congress, Cape Town, January 2013 **– INVITED KEYNOTE ADDRESS.**

[6] **MAARMAN G**, Recent developments in PAH Basic Science research and Animal models, PVRI Annual Congress, Cape Town, January 2012 **– INVITED KEYNOTE ADDRESS.**

**CONFERENCE OUTPUTS (PEER-REVIEWED)**

[1] **MAARMAN G**, Brittany Andrew, D Blackhurst, Ojuka E, Melatonin rescues uric acid-induced mitochondrial impairment and oxidative stress in C2C12 myotubes Khütai Austria, 7-13th July 2016.

[2] **MAARMAN G**, Brittany Andrew, D Blackhurst, Ojuka E, Uric acid impairs mitochondrial respiration, elevates triglycerides, reduce aconitase activity: Melatonin counteracts these effects, Experimental Biology, San Diego California, United States of America, April 2016.

[3] Marais E, Huisamen B, **MAARMAN G**, Lochner A, Cardiovascular abnormalities in aged, diet-induced obese rats, to be presented at the Physiology Society of Southern Africa, 35th Annual Congress, Johannesburg South Africa 2015.

[4] F. Thienemann, L. Blauwet, R. Burton, K. Tibazarwa, **MAARMAN G**, A. Dzudie, A. O. Mocumbi, K. Sliwa, HIV-associated pulmonary hypertension in a densely populated, peri-urban township in Cape Town, South Africa: clinical presentation and survival, To be presented at the European Society of Cardiology (ESC) Annual meeting in Barcelona Spain, 30th August until 3rd of September 2014.

[5] **MAARMAN G**, Blauwet L, Blackhurst D, Sliwa K and Lecour S, Cardioprotective effect of melatonin on cardiac function and oxidative stress in pulmonary arterial hypertension, International Society of Heart Research, Barcelona, Spain, 2014.

[6] **MAARMAN G**, Blauwet L, Sliwa K and Lecour S, Effects of melatonin treatment on cardiac function in a model of pulmonary arterial hypertension, Pan-African Society of Cardiology Congress, Dakar, Senegal, 2013.

[7] **MAARMAN G**, Blauwet L, Lecour S and Sliwa K, Can melatonin improve cardiac function in pulmonary arterial hypertension? European Society of Cardiology (ESC) annual congress, Amsterdam, Netherlands 2013, European Heart Journal 2013; Vol 34(1):476.

[8] **MAARMAN G**, Blauwet L, Sliwa K, Lecour S, The effects of melatonin on cardiac function in a model of pulmonary arterial hypertension, The World Congress on Paediatric Cardiology & Cardiac Surgery 2013, Cape Town, South Africa.

[9] **MAARMAN G**, Du Toit E.F, The effect or a fatty acid oxidation inhibitor (oxfenicine) on myocardial function and –resistance to ischemia/reperfusion injury in a rodent model of the metabolic syndrome, Physiology Society of Southern Africa, 36th Annual Congress, Johannesburg, South Africa 2009.

[10] **MAARMAN G**, Du Toit E.F, The effect or a PPAR-alpha agonist (K111) on myocardial function and resistance to ischemia/reperfusion injury in a rodent model of the metabolic syndrome, Physiology Society of Southern Africa, 35th Annual Congress, Johannesburg South Africa 2008

**MEMBERSHIP OF PROFESSIONAL ASSOCIATIONS**

* **FACULTY MEMBER:** Pulmonary Vascular Research Institute (PVRI) Global Taskforce on Pulmonary Infections.
* **MEMBER:** American College of Chest Physicians
* **MEMBER:** American Heart Association
* **MEMBER:** American Thoracic Society
* **MEMBER:** International Society of Heart Research (ISHR) – European Section
* **MEMBER:** European Society of Cardiology (ESC)
* **MEMBER:** South African Society of Cardiovascular Research (SASCAR)
* **MEMBER:** Physiological Society of Southern Africa (PSSA)
* **MEMBER:** South Africa Heart Association (SA-Heart)

**AWARDS & NOMINATIONS**

* NRF Y2 rating
* Nomination, TW Kambule-NSTF Researcher Award (2023 & 2024)
* Nomination, TW Kambule-NSTF Emerging Researcher Award (2023 & 2024)
* Clinical excellence award, South African Heart Association (2012)
* Award of excellence, SU Akademiese Jaardag (2009)
* Award of excellence, 7th Mitochondrial Physiology School (2015)

**REFEREES**

**LINE MANAGER - PROF. HANS STRIJDOM**

Deputy Director: Centre for Cardio-Metabolic Research in Africa (CARMA).

Acting Head: Division of Medical Physiology, Faculty of Medicine and Health Sciences, Stellenbosch, University.

Work phone: 021 938 9387 Email: jgstr@sun.ac.za

**PROF. SANDRINE LECOUR**

Deputy Director of the Cape Heart Institute (CHI).

Faculty of Health Sciences, Department of Medicine, University of Cape Town. Work phone: 021 406 6358

Email: sandrine.lecour@uct.ac.za

**PROF. KAREN SLIWA**

Deputy Dean of Research, Department of Medicine, Faculty of Health Sciences, UCT. President of the World Heart Federation.

Director of the Cape Heart Institute (CHI). Work phone: 021 406 6457

Email: karen.sliwa-hahnle@uct.ac.za

**MR. LWANDO BANTOM**

National Director – Transformation and Growth

South African Institute of Chartered Accountants (SAICA) Tel: 041-3951500

Cell: 0724995267 and Email: lwandob@saica.co.za